[Tumour markers in epithelial ovarian cancer].
In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics.
Sparholt
Morten H
MH
Rigshospitalet, Juliane Marie Centret, Gynaekologisk Afdeling, Denmark. sparholt@stud.ku.dk
Høgdall
Estrid
E
Høgdall
Claus K
CK
D014408:Biomarkers, Tumor / Q000032:analysis*; D018394:CA-125 Antigen / Q000032:analysis*; D017024:Chemotherapy, Adjuvant; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008403:Mass Screening; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000601:surgery; D057285:Precision Medicine; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen